JLE

Hématologie

MENU

New therapeutic approaches in cutaneous T-cell lymphomas Volume 23, issue 4, Juillet-Août 2017

Tables

Authors
1 Service d’hématologie, Institut Jules-Bordet (ULB), Bruxelles, Belgique
2 Service de dermatologie, hôpital Saint-Pierre, Bruxelles, Belgique
* Tirés à part

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of T-cell neoplasms presenting in the skin, Mycosis Fungoides (MF) being the most common subtype and Sézary syndrome the leukemic form. Treatment is dependant on stage and responses to previous therapy. Treatments are divided into “skin-directed therapies” which are first-line for early stage diseases and “systemic therapie” reserved for advanced stages or refractory CTCL.

There are currently no curative therapies for CTCL and consecutive treatments have to be given in function of the progression of the disease. There is an urgent need for new therapies to treat symptoms, particularly pruritus and pain, and to prolong survival. This paper summarizes new drugs available for the CTCL and their mode of action.

Most new drugs for CTCL have response rates between 30% and 50% with response durations being less than a year. New studies looking at combination or maintenance therapies may improve quality of life and disease outcome.